Pharmaceutical

Dalfampridine IR by Solaxa for Spinocerebellar Ataxia (SCA): Likelihood of Approval

Dalfampridine IR is under clinical development by Solaxa and currently in Phase II for Spinocerebellar Ataxia (SCA).

Jul 6, 2024 - 04:00
Dalfampridine IR is under clinical development by Solaxa and currently in Phase II for Spinocerebellar Ataxia (SCA).
Read the original article

Tags:

Previous Article

LP-184 by Starlight Therapeutics for Non-Small Cell Lung Cancer: Likelihood of A...

Next Article

AZD-2389 by AstraZeneca for Metabolic Dysfunction-Associated Steatohepatitis (MA...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Obscure vertigo drug could bring rare hope for patients with devastating neuron disease

STAT+: Obscure vertigo drug could bring rare hope for p...

Feb 1, 2024

STAT+: FDA cites Fresenius Kabi for contamination problems that CDC linked to deadly sepsis cases

STAT+: FDA cites Fresenius Kabi for contamination probl...

Oct 4, 2023

Zydus Lifesciences gets grant for oral suspension of mycophenolate mofetil

Zydus Lifesciences gets grant for oral suspension of my...

Jun 8, 2024